Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

CLNN

Clene Inc

Dec 13 • 03:44PM ET

4.94

Dollar change -0.02
Percentage change -0.40	%

Consumer Defensive • Packaged Foods • USA • NASD

Peers: CYCN IMNM KNSA MTEM NAII PAVM RARE TERN XAIR

| Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.28	Insider Own	36.53%	Shs Outstand	137.14M	Perf Week	12.27%
Market Cap	39.42M	Forward P/E	-	EPS next Y	-3.42	Insider Trans	4.40%	Shs Float	5.06M	Perf Month	2.49%
Income	-36.02M	PEG	-	EPS next Q	-0.97	Inst Own	12.91%	Short Float	2.14%	Perf Quarter	-11.63%
Sales	0.42M	P/S	93.86	EPS this Y	52.66%	Inst Trans	-	Short Ratio	1.26	Perf Half Y	-35.53%
Book/sh	-0.03	P/B	-	EPS next Y	23.15%	ROA	-78.31%	Short Interest	0.11M	Perf Year	-39.81%
Cash/sh	1.83	P/C	2.69	EPS next 5Y	-	ROE	-416.92%	52W Range	3.82 - 12.00	Perf YTD	-16.72%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-18.22%	ROI	-503.90%	52W High	-58.83%	Beta	0.30
Dividend TTM	-	Quick Ratio	0.82	Sales past 5Y	50.93%	Gross Margin	-316.15%	52W Low	29.38%	ATR (14)	0.48
Dividend Ex-Date	-	Current Ratio	0.83	EPS Y/Y TTM	41.82%	Oper. Margin	-8163.42%	RSI (14)	55.61	Volatility	11.87% 11.14%
Employees	85	Debt/Eq	-	Sales Y/Y TTM	-41.36%	Profit Margin	-8556.77%	Recom	1.00	Target Price	51.43
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	-223.94%	Payout	-	Rel Volume	1.33	Prev Close	4.96
Sales Surprise	-18.46%	EPS Surprise	8.31%	Sales Q/Q	-19.44%	Earnings	Nov 13 BMO	Avg Volume	85.97K	Price	4.94
SMA20	13.02%	SMA50	-3.29%	SMA200	-20.69%	Trades		Volume	109,852	Change	-0.40%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-04-22	Downgrade	Oppenheimer	Outperform → Perform
Jul-18-22	Initiated	H.C. Wainwright	Buy	$16
May-02-22	Initiated	Canaccord Genuity	Buy	$10
Sep-28-21	Initiated	Oppenheimer	Outperform	$20

Dec-11-24 11:15AM	IBN Coverage: Clene (NASDAQ: CLNN) Advances CNM-Au8 in ALS With FDA Guidance on Accelerated Approval Pathway (NewMediaWire)
Dec-10-24 08:30AM	FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8 Biomarker Data in ALS (GlobeNewswire)
Nov-15-24 07:11AM	Clene price target lowered to $83 from $86 at Canaccord (TipRanks)
Nov-13-24 08:00AM	Clene Reports Third Quarter 2024 Financial Results and Recent Operating Highlights (GlobeNewswire) -9.06%
Oct-25-24 12:09PM	IBN Coverage: Clene (NASDAQ: CLNN) Set to Discuss Lead Candidate Biomarker With FDA Leadership (NewMediaWire)
01:13PM	Loading…
Oct-21-24 01:13PM	IBN Coverage: Clene (NASDAQ: CLNN) Presents Lead Candidate CNM-Au8(R) Updates at Investor Conferences (NewMediaWire)
Oct-11-24 02:55PM	IBN Coverage: Clene (NASDAQ: CLNN) Closes $7.3M Registered Direct Offering and Concurrent Private Placements (NewMediaWire)
Oct-09-24 01:31PM	IBN Coverage: Clene (NASDAQ: CLNN) Announces Participation at Two Upcoming Investor Conferences (NewMediaWire) +14.04%
08:00AM	Clene to Present at Upcoming October Conferences (GlobeNewswire)
Oct-03-24 10:46AM	IBN Coverage: Clene (NASDAQ: CLNN) Closes on Direct Offering, Concurrent Private Placements Totaling $7.3M (NewMediaWire)
Oct-02-24 07:21AM	IBN Coverage: Clene (NASDAQ: CLNN) Announces Series of Direct Offerings, Concurrent Private Placements (NewMediaWire) +6.30%
Oct-01-24 04:00PM	Clene Announces Closing of $7.3 Million Registered Direct Offering and Concurrent Private Placements and Amendment of Debt Facility (GlobeNewswire)
Sep-30-24 08:30AM	Clene Announces $7.3 Million Registered Direct Offering and Concurrent Private Placements Priced at Market Under Nasdaq Rules (GlobeNewswire)
Sep-26-24 11:44AM	IBN Coverage: Clene (NASDAQ: CLNN) to Discuss CNM-Au8(R) Data FDA Leadership (NewMediaWire)
Sep-16-24 08:30AM	Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data (GlobeNewswire) -17.06%
11:27AM	Loading…
Sep-04-24 11:27AM	IBN Coverage: Clene (NASDAQ: CLNN) Management to Present at H.C. Wainwright Investment Conference (NewMediaWire) +12.50%
Sep-03-24 10:38AM	IBN Coverage: Clene (NASDAQ: CLNN) Positioned as Leader in Addressing Neurodegenerative Diseases (NewMediaWire) +12.33%
08:00AM	Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-29-24 12:13PM	IBN Coverage: Clene (NASDAQ: CLNN) CEO Discusses CNM-Au8(R) Trial Results on BioMedWire Podcast (NewMediaWire)
Aug-23-24 10:17AM	IBN Coverage: Clene's (NASDAQ: CLNN) CNM-Au8(R) Affects Key Biomarkers, Long-term Survival in ALS Trials (NewMediaWire)
Aug-13-24 12:47PM	IBN Coverage: Clene (NASDAQ: CLNN) Makes Strides in Developing CNM-Au8(R) to Address Neurodegenerative Conditions (NewMediaWire)
Aug-12-24 08:00AM	IBN Coverage: Clene (NASDAQ: CLNN) CEO Spotlighted in Recent BioMedWire Podcast Episode (NewMediaWire)
Aug-09-24 09:00AM	IBN Coverage: Clene (NASDAQ: CLNN) Releases Q2 2024 Financial Results, Provides Updates (NewMediaWire) +14.74%
Aug-08-24 08:00AM	IBN Announces Latest Episode of The BioMedWire Podcast featuring Rob Etherington, CEO of Clene Inc. (GlobeNewswire)
Aug-07-24 08:23AM	Clene Reports Second Quarter 2024 Financial Results and Recent Operating Highlights (GlobeNewswire) -23.47%
Aug-06-24 08:00AM	Clene Announces New CNM-Au8 Biomarker and Clinical Efficacy Data Submitted to FDA In Support of Treatment For ALS (GlobeNewswire) +47.00%
Aug-05-24 08:00AM	Clene to Present at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase (GlobeNewswire) -7.62%
Jul-17-24 07:00AM	Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now (GlobeNewswire)
Jul-16-24 07:00AM	Presenting on the Emerging Growth Conference 73 Day 1 on July 17 Register Now (GlobeNewswire)
Jul-12-24 10:34AM	Clene to Present at the Emerging Growth Conference (GlobeNewswire)
09:00AM	Loading…
Jul-11-24 09:00AM	Clene Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval for CNM-Au8 in ALS (GlobeNewswire) -9.61%
Jul-09-24 08:00AM	Clene Announces 1-for-20 Reverse Stock Split (GlobeNewswire) -21.54%
Jun-24-24 08:00AM	Clene to Present at H.C. Wainwright's 5th Annual Neuro Perspectives Virtual Conference (GlobeNewswire)
Jun-21-24 07:09AM	Clene Presents Preliminary Data for CNM-Au8 as a Potential Treatment for Rett Syndrome (GlobeNewswire)
Jun-18-24 07:37AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
07:00AM	Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting (GlobeNewswire)
Jun-12-24 07:46AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
07:00AM	Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now (GlobeNewswire)
Jun-11-24 07:00AM	Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now (GlobeNewswire)
Jun-05-24 08:00AM	Clene to Present at the Emerging Growth Conference (GlobeNewswire)
May-28-24 07:30AM	Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8 in ALS (ACT-EAP) (GlobeNewswire)
May-14-24 08:00AM	Clene to Present at Upcoming May Conferences (GlobeNewswire)
May-10-24 07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
May-08-24 12:54PM	CLNN Stock Earnings: Clene Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:55AM	Clene Inc. (CLNN) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
08:00AM	Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights (GlobeNewswire)
06:00AM	3 Speculative Penny Stocks Offering High-Upside Potential for Under a Buck (InvestorPlace)
May-01-24 08:30AM	IBN Announces From Lab to Launch Podcast Featuring Clene Inc. CEO Rob Etherington (GlobeNewswire)
Apr-16-24 04:01PM	Evidence for Clene's CNM-Au8 as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting (GlobeNewswire) -6.46% +9.55%
Mar-19-24 08:30AM	IBN Announces First in Human Podcast Featuring Clene Inc. CEO Rob Etherington (GlobeNewswire)
Mar-15-24 08:00AM	Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8® (GlobeNewswire)
Mar-13-24 09:30AM	Clene Inc. (CLNN) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights (GlobeNewswire)
Mar-07-24 08:00AM	Clene to Present at the 36th Annual ROTH Conference (GlobeNewswire)
Feb-29-24 08:00AM	Clene Presents Clinical Results of CNM-Au8 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024 (GlobeNewswire) -7.28%
Feb-22-24 08:00AM	Clene Reports Significant Survival Benefit With CNM-Au8 Treatment in ALS EAP Compassionate Use Programs (GlobeNewswire)
Feb-05-24 02:30PM	Clene Inc. announces positive results from CNM-Au8 results from MS trial (News Direct) -6.18%
Jan-24-24 08:30AM	Clene VISIONARY-MS Trial Data May Support CNM-Au8(R) as MS Treatment (NewMediaWire) +9.11%
Jan-10-24 09:00AM	Clene Announces Significant Positive Results from LTE VISIONARY-MS Trial (NewMediaWire)
Jan-08-24 07:00AM	Clene Reports Significant Improvement in Vision and Cognition With CNM-Au8 Treatment in VISIONARY-MS Trial Long-Term Open Label Extension (GlobeNewswire) +22.07%
Jan-03-24 04:25PM	Clene's Phase 2 REPAIR-PD and REPAIR-MD Trials Support Advancement to Phase 3 (NewMediaWire)
Dec-22-23 03:00PM	Clene Announces New Data from HEALEY ALS Platform Trial (NewMediaWire) -7.94%
Dec-21-23 07:46AM	FDA unconvinced by Clene's request for ALS therapy's accelerated approval tag (FierceBiotech.com) -38.83%
07:00AM	Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8 Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension (GlobeNewswire)
07:00AM	Clene Provides Update on ALS Clinical Development Meeting With FDA (GlobeNewswire)
Dec-19-23 09:00AM	How Clene CNM-Au8(R) Takes Advantage of Gold Nanocrystals to Target Neurodegenerative Disorders (NewMediaWire) +9.35%
Dec-15-23 03:00PM	Clene Lead Drug Candidate Featured in Peer-Reviewed Publication (NewMediaWire)
Dec-14-23 08:36AM	Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement In Neurodegenerative Diseases (GlobeNewswire)
Dec-12-23 08:30AM	Clene's Long-Term Follow-Up Data Shows Significantly Improved Survival in ALS Patients (NewMediaWire) -6.45%
Dec-08-23 02:19PM	Nobel Prize in Chemistry's Spotlight on Nanotechnology Shines Light on Clene Efforts to Develop Catalytically Active Nanoparticles (NewMediaWire)
Nov-23-23 09:00AM	Clene Capitalizing on Promising Chemical and Therapeutic Properties of Nanocrystals (NewMediaWire)
Nov-14-23 08:30AM	Clene Among Grant Awardees Selected to Advance Scientific Research on ALS (NewMediaWire) -6.78%
Nov-09-23 09:00AM	Clene Announces Q3 2023 Financial Results, Operating Highlights (NewMediaWire)
Nov-07-23 08:57AM	Clene Inc (CLNN) Reports Q3 2023 Financial Results: Significant Survival Benefits and $45. ... (GuruFocus.com) +8.02%
08:00AM	Clene Reports Third Quarter 2023 Financial Results and Operating Highlights (GlobeNewswire)
Oct-31-23 08:30AM	Clene Reports Improved Survival Status in ALS Patients Treated with CNM-Au8(R) on Follow-Up Analysis (NewMediaWire)
Oct-26-23 08:30AM	Clene Announces Four-Year Grant to Support Expanded Access Protocol for CNM-Au8 From NINDS (NewMediaWire)
Oct-19-23 08:30AM	Clene 'Innovates' Investigational Drug With Patented Nanotechnology (NewMediaWire)
Oct-17-23 08:30AM	Clene Applies Patented Nanotechnology to Development of CNM-Au8(R), Its Investigational Drug for ALS (NewMediaWire) -5.77%
Oct-11-23 09:00AM	Clene CEO Featured in Latest Episode of The Bell2Bell Podcast (NewMediaWire)
Oct-06-23 02:15PM	Clene Announces $45.1M NINDS Grant (NewMediaWire)
Oct-05-23 10:00AM	National Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8 Study in ALS (GlobeNewswire) +9.98%
Sep-29-23 03:00PM	Clene Investigational Drug Focus of Study Published in Peer-Reviewed Journal (NewMediaWire)
08:30AM	Clene Inc. Is 'One to Watch' (NewMediaWire)
Sep-28-23 08:00AM	Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Catalytic Neuroprotective Mechanism of Action (GlobeNewswire) -5.30%
Sep-27-23 09:00AM	Clene Releases Significant Long-Term Survival Improvement Data from ALS Trial (NewMediaWire)
Sep-25-23 04:00PM	Clene to Present at Cantor Fitzgerald Annual Global Healthcare Conference (GlobeNewswire) +13.15%
07:00AM	Clene Reports Significant Long-Term Survival Improvement From CNM-Au8 Treatment in HEALEY ALS Platform Trial Compared to PRO-ACT Historical Controls (GlobeNewswire)
Aug-30-23 08:20AM	Clene to Present at Upcoming September Conferences (GlobeNewswire) +7.94%
Aug-29-23 07:00AM	Clene Reports Significantly Improved Survival Benefit of 19.3 Months and Significantly Delayed Clinical Worsening in Rescue-Als Open-Label Extension Two Year Follow-Up (GlobeNewswire)
Aug-14-23 08:00AM	Clene Reports Second Quarter 2023 Financial Results and Operating Highlights (GlobeNewswire)
Aug-02-23 07:00AM	Clene to Present at the Canaccord Genuity 43rd Annual Growth Conference (GlobeNewswire)
Jun-28-23 11:19AM	Insiders Pour Millions Into These 2 Strong Buy Stocks Heres Why You Might Want to Steer Toward Them Too (TipRanks) +5.14%
07:13AM	Daily Vickers Top Buyers & Sellers for 06/28/2023 (Argus Research)
Jun-26-23 08:00AM	Clene Announces Publication of Phase 2 CNM-Au8® Clinical Data for the Treatment of ALS in LANCETs eClinicalMedicine (GlobeNewswire)
Jun-21-23 09:20AM	Clene Welcomes New Shareholder Base and Announces Closing of Underwritten Public Offering of $40 Million (GlobeNewswire) -8.00%
07:20AM	Daily Vickers Top Buyers & Sellers for 06/21/2023 (Argus Research)
Jun-16-23 08:00AM	Clene Announces Pricing of $40 Million Public Offering (GlobeNewswire) -18.85%
Jun-15-23 04:38PM	Clene Announces Launch of Proposed Public Offering (GlobeNewswire)
04:29PM	Clenes CNM-Au8® Shows Statistically Significant Difference in Plasma Neurofilament Light (NfL) levels in the HEALEY ALS Platform Trial (GlobeNewswire)

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MATLIN DAVID J	Director	Sep 30 '24	Buy	4.75	92,307	438,458	444,491	Oct 02 12:58 PM
Mortenson Mark	Chief Science Officer	Sep 30 '24	Buy	4.75	20,512	97,432	28,949	Oct 01 04:17 PM
Etherington Robert Dee	Chief Executive Officer	Sep 30 '24	Buy	4.75	10,000	47,500	40,149	Oct 01 04:17 PM
Etherington Robert Dee	Chief Executive Officer	Jul 29 '24	Option Exercise	3.00	27,320	81,960	30,149	Jul 30 09:03 AM
General Resonance LLC	10% Owner	Apr 30 '24	Sale	0.42	13,000	5,416	15,326,712	May 08 12:16 PM
General Resonance LLC	10% Owner	May 01 '24	Sale	0.40	13,000	5,148	15,313,712	May 08 12:16 PM
General Resonance LLC	10% Owner	Apr 24 '24	Sale	0.33	10,000	3,278	15,349,712	May 01 05:13 PM
General Resonance LLC	10% Owner	Apr 09 '24	Sale	0.39	22,500	8,674	15,428,212	Apr 16 09:38 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CLNN

Clene Inc

Upgrade your FINVIZ experience